Is BPC-157 legal? FDA status, Category 2 and WADA in 2026
BPC-157 is not banned in US law, not FDA approved and not compoundable under 503A. Its Category 2 history, the July 2026 committee vote and WADA S0, each dated to its source, as of October 2026.
Is BPC-157 legal? It is not banned or scheduled under US federal law, but it is not an FDA-approved drug, it is in no FDA compounding category, and it cannot lawfully be compounded under section 503A. It left FDA's Category 2 in April 2026 because its nominations were withdrawn, not because FDA cleared it, and in sport it is banned at all times under WADA section S0. As of October 21, 2026, FDA has published no rule or vote record that changes any of this.
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide: fifteen amino-acid residues, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, written in one-letter code as GEPPPGKPADDAGLV. PubChem (CID 9941957) gives the formula C62H98N16O22, an average molecular weight of 1419.5 and a monoisotopic mass of 1418.704, with CAS 137525-51-0 and the synonyms Bepecin, PL-14736 and PLD-116. PubChem describes it as a fifteen-residue fragment of a gastric peptide abbreviated BPC, for body protection compound, and lists "Gastric Juice Peptide Fragment" among its names. It carries no terminal modifications and no non-standard residues, and in the literature it is handled as the free base or the acetate salt. FDA's July 2026 advisory materials evaluated both forms separately.
Its human research record is thin. ClinicalTrials.gov held four BPC-157 records on October 21, 2026: a Phase 1 study in Mexico with an unknown status, a Phase 1 study at the University of Arkansas listed as not yet recruiting, a Phase 2 study by Hudson Biotech in China, and a completed dietary-gummy study by a wellness company. No sponsor is running a US pivotal program. We stock BPC-157 as a lyophilized research vial with a named manufacturer and a second independent assay, and that is all this article will say about our product.
Is BPC-157 banned or illegal?
No. There is no federal ban on BPC-157. It is not a controlled substance; the Controlled Substances Act's anabolic-steroid definition is built around substances "chemically and pharmacologically related to testosterone," and a fifteen-residue peptide is not one. FDA has never issued a rule prohibiting it. What FDA has done is regard it as an unapproved new drug when it is sold with claims, which is a statement about the seller's intent rather than a prohibition on the molecule.
The word "banned" does apply in one arena, and it is sport, not law. WADA's 2026 Prohibited List names BPC-157 as an example under section S0, the class for substances not approved by any government regulator, prohibited at all times. S0 is the class for substances with no approval anywhere, so WADA's placement is itself a statement of BPC-157's regulatory status, and BPC-157 has been an S0 example since the 2022 List; the 2026 release notes no change. It is not in S2 with the growth hormone releasing factors and growth factors. The S0 text, and how the WADA sections map onto research peptides, is set out in WADA S0, S2 and where research peptides sit on the Prohibited List.
What is BPC-157's FDA status?
No. There is no BPC-157 product in Drugs@FDA, and the paperwork trail says so from several directions. The 503A bulks list, to which BPC-157 was nominated, is reserved by statute for substances that have no USP or NF monograph and are not "components of drugs approved by the Secretary." A nomination to that list is an acknowledgment that no approved product exists. WADA's S0 wording, quoted above, says the same thing in different words. How this compares with peptides that do have approved products is in the FDA approved peptides status table.
FDA's own description of the substance, written when it placed BPC-157 in Category 2 on September 29, 2023, is still on the agency's Category 2 page (content current as of April 22, 2026). In our words: compounded BPC-157 may carry a risk of immunogenicity for some routes, may raise complexities around peptide-related impurities and characterization of the active ingredient, and FDA found no, or only limited, safety information for the proposed routes, so it lacks the information to know whether the substance would cause harm in people.
Approval would require a sponsor to file an application under section 505 with the evidence that FDA says it does not have. No such application is public, and the only US drug trial on the register has not begun recruiting.
Is BPC-157 still in Category 2, and can it be compounded?
No to both. Under section 503A, the statute allows a state-licensed pharmacy or a physician to compound from a bulk substance only if that substance (1) has a USP or NF monograph, (2) is a component of an FDA-approved drug, or (3) is on the 503A bulks list. BPC-157 has no monograph, is a component of no approved drug, and is not on the list, which in 21 CFR 216.23, as published on eCFR for October 15, 2026, holds six substances and no peptides.
What changed in 2026 was FDA's interim sorting, and the change was made by the nominators, not by FDA. From September 29, 2023 BPC-157 sat in 503A Category 2, the group FDA says "may present significant safety risks." On FDA's page dated April 22, 2026 it appears under "Bulk drug substances nominated but withdrawn," with the sentence that the substances "were withdrawn by the nominators." After withdrawal BPC-157 is in no category. It is not in Category 1, where FDA's stated policy is that it "does not intend to take action against a compounder" while evaluation continues; the Category 1 document updated May 14, 2026 does not contain it. So the enforcement discretion that people mean when they say "legal to compound" does not reach BPC-157.
On July 23, 2026 FDA put BPC-157 free base and BPC-157 acetate to the Pharmacy Compounding Advisory Committee, having stated its own position in the briefing document: "FDA is proposing that BPC-157 (free base) NOT be included on the 503A Bulks List." Press reports (TIME and OpenLoop Health) give the committee's vote as 8 yes, 6 no and 1 abstention. FDA has published no vote record, and the committee's recommendations are, in FDA's words, "non-binding." Adding a substance to the list requires rulemaking. As of October 21, 2026 no proposed rule, notice or press release on BPC-157 has appeared on fda.gov or federalregister.gov. The three 2026 events and their tracker are in Category 1, Category 2 and the 503A bulks list.
On the 503B side, BPC-157 does not appear in any category of FDA's 503B list dated March 21, 2025. It was never in 503B Category 2, where the peptide entries are GHRP-2, GHRP-6 and ipamorelin acetate.
Where the "legal now" story came from
Three substitutions produce the headline. "Withdrawn from Category 2" is read as "cleared by FDA," when the withdrawal was the nominators' and FDA's safety text is still posted. "A committee majority voted yes" is read as "FDA voted yes," when the tally is a press figure, the committee is advisory, and FDA staff recommended the opposite. "FDA is considering the bulks list" is read as "it is on the bulks list," when the list is a codified regulation that has not been amended. Each substitution moves BPC-157 one step closer to a pharmacy shelf than any FDA document places it.
BPC-157 legal status at a glance (as of October 2026)
| Question | Answer | Source |
|---|---|---|
| Controlled substance? | No | 21 U.S.C. 802(41) |
| FDA-approved product? | No | Drugs@FDA; 503A nomination record; WADA S0 wording |
| US trials? | One Phase 1, not yet recruiting (University of Arkansas); no sponsor-run pivotal program | ClinicalTrials.gov, October 21, 2026 |
| 503A category? | None; Category 2 from September 29, 2023 until nominations withdrawn, page dated April 22, 2026; not in Category 1 (May 14, 2026 list) | FDA Category 2 page; FDA Category 1 document |
| On the 503A bulks list? | No | 21 CFR 216.23 |
| FDA's July 2026 position? | Proposed that neither free base nor acetate be added | PCAC briefing document |
| PCAC vote? | 8-6-1 in favor, as reported by press; no FDA tally; non-binding | TIME; OpenLoop Health; FDA meeting page |
| Rulemaking since? | None found | fda.gov; federalregister.gov |
| 503B category? | None | FDA 503B list, March 21, 2025 |
| WADA 2026? | S0, prohibited at all times, Specified Substance | WADA 2026 Prohibited List |
Nothing in this article changes what a research vial is: a chemical of stated identity and purity, supplied for laboratory work, with a third-party laboratory's certificate that says what is in it, and the line this site draws around it is in what "research use only" actually means.
Frequently asked questions
Is BPC-157 legal in the United States?
It is not a controlled substance and no federal rule prohibits the molecule. It is also not FDA approved and has no lawful 503A compounding pathway, as of October 21, 2026. FDA regards it as an unapproved new drug when it is sold with claims for use in people.
Is BPC-157 banned?
Not in US law. In sport, yes: WADA's 2026 Prohibited List names BPC-157 under S0, non-approved substances, prohibited in and out of competition.
What is BPC-157's FDA status?
There is no approved BPC-157 product in Drugs@FDA. It is in no 503A category, is not on the 503A bulks list in 21 CFR 216.23, and appears in no 503B category. FDA staff proposed in July 2026 that it not be added to the bulks list.
Is BPC-157 still Category 2?
No. It was in 503A Category 2 from September 29, 2023. FDA's page dated April 22, 2026 lists it under "nominated but withdrawn," because the nominators withdrew. FDA's safety text for it is still posted, and it did not move to Category 1.
Did the July 2026 committee vote make BPC-157 legal to compound?
No. Press reports give the vote as 8 yes, 6 no and 1 abstention, but the committee is advisory and FDA's briefing document proposed against listing it. Adding it would take rulemaking, and none has appeared as of October 2026.
Sources
- BPC-157, PubChem CID 9941957, National Library of Medicine
- ClinicalTrials.gov search for BPC-157, National Library of Medicine, queried October 21, 2026
- Certain bulk drug substances for use in compounding that may present significant safety risks, FDA, content current as of April 22, 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (PDF), FDA, updated May 14, 2026
- Bulk drug substances used in compounding under section 503A, FDA, content current as of May 14, 2026
- 503B bulk drug substance categories (PDF), FDA, updated March 21, 2025
- 21 CFR 216.23, eCFR, as of October 15, 2026
- Federal Register documents mentioning BPC-157, federalregister.gov, searched October 21, 2026
- PCAC Briefing Document, Introduction (PDF), FDA, July 2026
- Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026, FDA, content current as of August 6, 2026
- FDA committee votes on peptides, TIME, July 23, 2026
- The 2026 Prohibited List, WADA, valid January 1, 2026
- 21 U.S.C. 802, Definitions, U.S. Code, current
For laboratory research use only. Not a drug, not a supplement, and nothing here is a claim about what any of this material does in a person or an animal.
